<SEC-DOCUMENT>0000950170-24-056934.txt : 20240509
<SEC-HEADER>0000950170-24-056934.hdr.sgml : 20240509
<ACCEPTANCE-DATETIME>20240509160839
ACCESSION NUMBER:		0000950170-24-056934
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20240509
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240509
DATE AS OF CHANGE:		20240509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARS Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001671858
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				811489190
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39756
		FILM NUMBER:		24930580

	BUSINESS ADDRESS:	
		STREET 1:		11682 EL CAMINO REAL, SUITE 120
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		858-771-9307

	MAIL ADDRESS:	
		STREET 1:		11682 EL CAMINO REAL, SUITE 120
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Silverback Therapeutics, Inc.
		DATE OF NAME CHANGE:	20160412
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>spry-20240509.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-05-09T12:33:27.9070+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:spry="http://ars-pharma.com/20240509" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_07235a38-c496-4174-8f10-a79c6a4a9416" name="dei:EntityCentralIndexKey" contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae">0001671858</ix:nonNumeric><ix:nonNumeric id="F_d4c34378-3ae2-497a-a50c-680f964ce606" name="dei:AmendmentFlag" contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae" format="ixt:fixed-false">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="spry-20240509.xsd"/></ix:references><ix:resources><xbrli:context id="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-09</xbrli:startDate><xbrli:endDate>2024-05-09</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div class="section-group" style="margin:auto;padding-left:1in;width:6.5in;padding-right:1in;"><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a80573e7-3ca1-439e-b7c5-cbfd06498d33" contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 13 or 15(d)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">of the Securities Exchange Act of 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_56ea463c-2535-4a40-8776-1034d798693a" contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">May 9, 2024</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Date of Report (Date of earliest event reported)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5b2466a6-2d96-4f85-bf31-e0f15243a45e" contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;">ARS Pharmaceuticals, Inc.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:34%;"/>
     <td style="width:1%;"/>
     <td style="width:32%;"/>
     <td style="width:1%;"/>
     <td style="width:32%;"/>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_2afddfb2-683d-438a-a546-d2f8e4ec6e6d" contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_c5707acf-6e64-4914-bacf-54d9a8219b3b" contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">001-39756</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_3d5945bf-91e2-49ce-a398-e189743e1c3e" contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">81-1489190</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or other jurisdiction</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">of incorporation)</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Commission</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">File Number)</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(IRS Employer</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identification No.)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50.5%;"/>
     <td style="width:1.02%;"/>
     <td style="width:48.48%;"/>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span><ix:nonNumeric id="F_32c39d13-333b-41d1-a705-d3d1bbe923c8" contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">11682 El Camino Real</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_c239757e-3a88-41c7-9296-42da318037c2" contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Suite 120</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span><ix:nonNumeric id="F_bb243c9a-5aba-4967-8f7b-1bb960e33cf1" contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">San Diego</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_dbaff821-06fe-4321-9bd8-50a6efd3b933" contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_6ccd6ce5-255c-4c8d-8c08-c01c25da130b" contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">92130</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1ff39691-e150-4d79-bc62-00b7df29b113" contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(858)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_abb98eda-b482-4e68-ad61-18dc16f48f20" contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">771-9307</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not Applicable</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Former name or former address, if changed since last report.)</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:3.28%;"/>
     <td style="width:96.72%;"/>
    </tr>
    <tr style="height:11pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_abbd9e97-f63a-4f93-bb1f-b6499b894385" contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p></td>
    </tr>
    <tr style="height:11pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_64587add-f5c0-4381-8429-6ee8bea9e963" contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p></td>
    </tr>
    <tr style="height:11pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_f646ce40-4c95-482e-983a-2cdd9c1065ff" contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p></td>
    </tr>
    <tr style="height:11pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_08ada183-175f-41a3-b6d2-f31c6ad86aed" contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:34%;"/>
     <td style="width:1%;"/>
     <td style="width:32%;"/>
     <td style="width:1%;"/>
     <td style="width:32%;"/>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of each class</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Symbol(s)</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of each exchange</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">on which registered</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_27555bba-b679-4ce4-adce-3596ee34e81c" contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_8bf93723-adc6-4d0b-9428-e84723956237" contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">SPRY</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_5870583b-7e8d-4069-b14b-005a6243df1c" contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b&#8211;2 of the Securities Exchange Act of 1934 (&#167; 240.12b&#8211;2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company </span><span style="font-size:12pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_468e6093-94a7-41d7-9c59-41618c24e8f1" contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_fdf79cbc-5594-4cb8-a0ec-db5b2d3fc3b6" contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
   <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="s88fc7c5dc8f252f1a4d1160e76b498f0"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2.02 Results of Operations and Financial Condition.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On May 9, 2024, ARS Pharmaceuticals, Inc. (the &#8220;Company&#8221;) announced its financial results for the quarter ended March 31, 2024 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information in this Item 2.02 of this Current Report on 8-K, including Exhibit 99.1, is furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today&#8217;s date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:0.003472222222222222in;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:10%;"/>
     <td style="width:90%;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Item 9.01</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial Statements and Exhibits.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(d)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:7%;"/>
     <td style="width:4.02%;"/>
     <td style="width:88.98%;"/>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
    </tr>
    <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99.1</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="spry-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Press Release dated May 9, 2024</span></a></p></td>
    </tr>
    <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
   <hr style="page-break-after:always;"/><div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:22%;"/>
     <td style="width:29.76%;"/>
     <td style="width:4%;"/>
     <td style="width:44.24%;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ARS PHARMACEUTICALS, INC.</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: May 9, 2024</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Richard Lowenthal, M.S., MSEL</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Richard Lowenthal, M.S., MSEL</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
   <hr style="page-break-after:always;"/></div>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>spry-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div class="section-group" style="margin:auto;padding-left:1in;width:6.5in;padding-right:1in;"><div style="padding-top:0.5in;min-height:1.12in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 99.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img41264513_0.jpg" alt="img41264513_0.jpg" style="width:168px;height:65px;">&#160;</p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:13pt;font-family:Times New Roman;min-width:fit-content;">ARS Pharmaceuticals Highlights </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:13pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:13pt;font-family:Times New Roman;min-width:fit-content;"> Regulatory Progress and Reports First Quarter 2024 Financial Results</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:13pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#174; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(epinephrine nasal spray) New Drug Application (NDA) and CRL response under review by FDA with anticipated review completion by early October 2024</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Response submitted for </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Marketing Authorization Application (MAA) to EMA&#x2019;s CHMP; CHMP opinion expected in the second quarter of 2024</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Preparing to initiate outpatient study of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">for urticaria (hives) in second half of 2024</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">$223.6 million in cash and securities as of March 31, 2024, providing an expected operating runway of at least three years; well-capitalized to support anticipated U.S. launch of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> in the second half of 2024<br><br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">SAN DIEGO -- May 9, 2024 </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today reported business updates and financial results for the first quarter of 2024.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;With the completion of all requested </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#174;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> (epinephrine nasal spray) studies and submission of our response to FDA, we believe we are very close to delivering the first needle-free, safe, effective, and easy to carry epinephrine solution to the millions of people living with Type I allergies including anaphylaxis. Our primary focus is ensuring we are well-positioned for a successful launch of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">in the U.S. upon approval, which is expected within the next six months. Importantly, we are well-capitalized with a multi-year operating runway that supports our </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> commercialization activities in the U.S.,&#x201d; said Richard Lowenthal, Co-founder, President and CEO of ARS Pharma. &#x201c;Our goal is to ensure that patients around the world have access to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> in a timely manner. We&#x2019;ve completed our submission to the EMA&#x2019;s CHMP and expect an opinion on our MAA this quarter. We&#x2019;re also delighted to partner with Australian pharmaceutical leader CSL Seqirus to support the approval and commercialization of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> in Australia and New Zealand. These positive updates reflect our team&#x2019;s strong execution and unwavering commitment to serving patients.&#x201d;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
   <hr style="page-break-after:always;"><div style="padding-top:0.5in;min-height:1.12in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">U.S. Regulatory Status of neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">for Type 1 Allergic Reactions</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p><div style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.5235502658900995%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In April, ARS Pharma submitted its response to the FDA&#x2019;s Complete Response Letter (CRL) issued regarding its NDA for </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">for the treatment of Type I allergic reactions including anaphylaxis. The response addressed all additional requests in FDA&#x2019;s CRL, which included the positive data from a repeat dose PK/PD study of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> under nasal allergen challenge conditions, and updated testing that detected no measurable nitrosamine levels, conducted per FDA&#x2019;s draft guidance issued in August 2023. ARS Pharma anticipates an FDA review period of up to six months, and the PDUFA date is anticipated to be October 2, 2024, based on the submission receipt date of April 2, 2024. Assuming approval on or before the anticipated PDUFA date, ARS Pharma anticipates launching </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> in the U.S. in the second half of 2024.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Global Regulatory Status of neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p><div style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.5235502658900995%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">On April 30, ARS Pharma also submitted its Day 180 response to the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for its MAA for </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Based on the timetable included in the Day 180 comments, ARS Pharma expects CHMP to issue its opinion on the </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> MAA later this quarter.</font></div></div><div style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.5235502658900995%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARS Pharma executed an exclusive license and distribution agreement for Australia and New Zealand with CSL Seqirus, a subsidiary of CSL Limited (ASX: CSL), which is the largest Australian pharmaceutical company. Under the terms of the agreement, CSL Seqirus plans to secure regulatory approval and reimbursement and commercialize </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">in Australia and New Zealand. ARS Pharma will receive an upfront payment as well as potential event-related milestone payments, with a combined value of up to $5 million. Following local regulatory approval of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, ARS Pharma will be responsible for supplying finished product to CSL Seqirus at a transfer price paid to ARS Pharma.</font></div></div><div style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.5235502658900995%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Submissions to other regulatory authorities in additional countries including China and Japan are planned for 2024.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical Expansion of neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">for Urticaria</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p><div style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.5235502658900995%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARS Pharma is on-track to initiate an outpatient study of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">for patients with urticaria, who have been previously treated with antihistamines and experience frequent acute flares. The Phase 2b trial is expected to begin dosing patients in the second half of 2024, followed by the potential initiation of a single pivotal efficacy study in 2025.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Additional Business Highlights</font></p><div style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.5235502658900995%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">On March 7, 2024, ARS Pharma held its first </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> Investor Day. ARS Pharma management was joined by two leading allergists, Dr. Jonathan Spergel, M.D., Ph.D., and Dr. Thomas B. Casale, M.D., who provided an overview of the treatment landscape for severe Type I allergies and a review of the positive clinical data submitted in the </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> registration package. A replay of the event can be accessed here.</font></div></div><div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
   <hr style="page-break-after:always;"><div style="padding-top:0.5in;min-height:1.12in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><div style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.5235502658900995%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In March 2024, results from the upper respiratory tract infection clinical study of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">were published in the </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Journal of Allergy and Clinical Immunology: In Practice. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The results demonstrated that the pharmacokinetic and pharmacodynamics of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">were not affected by upper respiratory tract infection symptoms.</font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">First Quarter 2024 Financial Results</font></p><div style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.5235502658900995%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Cash Position: </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Cash, cash equivalents and short-term investments were $223.6 million as of March 31, 2024, which ARS Pharma believes is sufficient to fund its current operating plan for at least three years. </font></div></div><div style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.5235502658900995%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">R&amp;D Expenses: </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Research and development (R&amp;D) expenses were $5.2 million for the quarter ended March 31, 2024, compared to $6.6 million for the quarter ended March 31, 2023. R&amp;D expenses decreased from 2023 to 2024 primarily due to a decrease in device development costs, partially offset by an increase in clinical trial costs.</font></div></div><div style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.5235502658900995%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">G&amp;A Expenses: </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">General and administrative (G&amp;A) expenses were $8.0 million for the quarter ended March 31, 2024, compared to $12.2 million for the quarter ended March 31, 2023. G&amp;A expenses decreased from 2023 to 2024 primarily due to a pause in pre-commercial launch activities related to</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div><div style="margin-left:0.33958333333333335in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.3402777777777778in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.5235502658900995%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Net Loss: </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Net loss was $10.3 million for the quarter ended March 31, 2024, compared to $15.0 million for the quarter ended March 31, 2023. </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">About Type I Allergic Reactions including Anaphylaxis</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Type I severe allergic reactions are serious and potentially life-threatening events that can occur within minutes of exposure to an allergen and require immediate treatment with epinephrine, the only FDA-approved medication for these reactions. While epinephrine autoinjectors have been shown to be highly effective, there are well published limitations that result in many patients and caregivers delaying or not administering treatment in an emergency situation. These limitations include fear of the needle, lack of portability, needle-related safety concerns, lack of reliability, and complexity of the devices. There are approximately 40 million people in the United States who experience Type I severe allergic reactions. Of those, only 3.2 million have an active epinephrine autoinjector prescription, and of those, only half consistently carry their prescribed autoinjector. Even if patients or caregivers carry an autoinjector, more than half either delay or do not administer the device when needed in an emergency.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
   <hr style="page-break-after:always;"><div style="padding-top:0.5in;min-height:1.12in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">About Urticaria</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Urticaria is a skin disorder that causes itchy hives and/or angioedema with an annualized incidence of 5 million in the United States, with about 40% becoming chronic urticaria; 50% of chronic urticaria cases are non-responsive to first-line antihistamine therapy. These non-responsive patients on stable therapy regimens can experience exacerbations or flares several times a year among acute cases, and even several times a week, including up to three or four emergency room visits per year. Angioedema is also a co-occurring symptom in about 33 to 67% of these patients. There are currently no approved community use treatments for acute flares experienced by urticaria patients on chronic regimens of antihistamines. ARS Pharma is investigating </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> for episodic symptomatic relief of these acute flares or exacerbations to improve the quality of life of urticaria patients. If </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">is approved for this indication, patients would have the option to quickly resolve exacerbations or flares at home without escalating to chronic use of systemic biologics that may have more serious side effects and benefit-risk considerations or visiting the emergency room for further treatment.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">About ARS Pharmaceuticals, Inc.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis. The Company is developing </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#174;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> (also referred to as ARS-1), an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications and insect bites that could lead to life-threatening anaphylaxis. For more information, visit www.ars-pharma.com.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Forward-Looking Statements</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Statements in this press release that are not purely historical in nature are &#x201c;forward-looking statements&#x201d; within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the anticipated timing for regulatory review decisions on the </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">NDA and MAA; our belief that </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">will be approved for the treatment of Type I allergic reactions; the timing for the potential U.S. launch of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, if approved; the planned outpatient study of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">for urticaria and the timing thereof; the potential initiation of a single pivotal efficacy study for </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">in urticaria and the timing thereof; ARS Pharma&#x2019;s projected cash runway; ARS Pharma&#x2019;s belief that it is well capitalized to support the launch of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> in the U.S., if approved; planned submissions of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to other foreign regulatory authorities for approval and the timing thereof; the potential benefits to urticaria patients if </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">is approved in this indication; and other statements that are not historical fact. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as &#x201c;anticipate,&#x201d; &#x201c;plans,&#x201d; &#x201c;believes,&#x201d; &#x201c;expects,&#x201d; &#x201c;on track to,&#x201d; &#x201c;will,&#x201d; &#x201c;potential&#x201d; and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon ARS Pharma&#x2019;s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the ability to obtain and maintain regulatory approval for </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">in any indication; even though the FDA has stated that completion of the repeat-dose study under allergen-induced allergic rhinitis conditions for </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> will sufficiently address the agency&#x2019;s outstanding questions, there is no guarantee that new issues will not be identified which could delay or prevent the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
   <hr style="page-break-after:always;"><div style="padding-top:0.5in;min-height:1.12in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">approval of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">; whether the FDA will view the results from ARS Pharma&#x2019;s repeat dose study under allergen induced allergic rhinitis conditions for </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> as sufficient to support approval for Type I allergic reactions; the PDUFA target action date may be further delayed due to various factors outside ARS Pharma&#x2019;s control; potential safety and other complications from </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">; the labelling for </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">in any indication, if approved; the scope, progress and expansion of developing and commercializing </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">; the size and growth of the market therefor and the rate and degree of market acceptance thereof vis-&agrave;-vis intramuscular injectable products; ARS Pharma&#x2019;s ability to protect its intellectual property position; uncertainties related to capital requirements; and the impact of government laws and regulations. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption &#x201c;Risk Factors&#x201d; in ARS Pharma&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on March 21, 2024, and in ARS Pharma&#x2019;s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, being filed with the SEC today. These documents can also be accessed on ARS Pharma&#x2019;s web page at ir.ars-pharma.com by clicking on the link &#x201c;Financials &amp; Filings.&#x201d;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The forward-looking statements included in this press release are made only as of the date hereof. ARS Pharma assumes no obligation and does not intend to update these forward-looking statements, except as required by law.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">###</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARS Investor Contacts:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Justin Chakma, ARS Pharmaceuticals</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">justinc@ars-pharma.com</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARS Media Contact:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Christy Curran, Sam Brown Inc.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">christycurran@sambrown.com</font></p><div style="flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;"></div>
   <hr style="page-break-after:always;"></div>
  <div class="section-group" style="margin:auto;padding-left:0.5in;width:7.5in;padding-right:0.5in;"><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ARS Pharmaceuticals, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Condensed Consolidated Balance Sheets</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share and par value data)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:66.313%;"></td>
     <td style="width:1.48%;"></td>
     <td style="width:1.48%;"></td>
     <td style="width:1%;"></td>
     <td style="width:12.623000000000001%;"></td>
     <td style="width:1%;"></td>
     <td style="width:1.48%;"></td>
     <td style="width:1%;"></td>
     <td style="width:12.623000000000001%;"></td>
     <td style="width:1%;"></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">March 31, 2024</font></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</font></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(unaudited)</font></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets:</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">56,006</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70,971</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">167,626</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">157,389</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,609</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,366</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current assets</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">226,241</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">231,726</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use asset</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">198</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">250</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed assets, net</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">616</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">574</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">528</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">638</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">227,583</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">233,188</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Liabilities and stockholders&#x2019; equity</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities:</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable and accrued liabilities (including related party amounts of $280 and $178, respectively)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,498</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,154</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liability, current</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">217</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">237</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current liabilities</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,715</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,391</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liability, net of current portion</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,715</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,428</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commitments and contingencies</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stockholders&#x2019; equity</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preferred stock, $0.0001 par value per share; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 2023</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock, $0.0001 par value per share; 200,000,000 shares authorized at March 31, 2024 and December 31, 2023; 96,574,049 and 96,414,963 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid-in capital</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">365,577</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">362,004</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated other comprehensive (loss) gain, net</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(124</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated deficit</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(141,595</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(131,303</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stockholders&#x2019; equity</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">223,868</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">230,760</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities and stockholders&#x2019; equity</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">227,583</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">233,188</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
   <hr style="page-break-after:always;"><div style="padding-top:0.5in;min-height:0.5in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ARS Pharmaceuticals, Inc.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Condensed Consolidated Statements of Operations and Comprehensive Loss</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share and per share data)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(unaudited)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:75.83%;"></td>
     <td style="width:1.1%;"></td>
     <td style="width:1%;"></td>
     <td style="width:8.984%;"></td>
     <td style="width:1%;"></td>
     <td style="width:1.1%;"></td>
     <td style="width:1%;"></td>
     <td style="width:8.984%;"></td>
     <td style="width:1%;"></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended March 31,</font></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</font></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</font></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue under collaboration agreements</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">20</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</font></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development (including related party amounts of $726 and $591, respectively)</font></p></td>
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5,234</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">6,552</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">General and administrative (including related party amounts of $93 and $337, respectively)</font></p></td>
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,958</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">12,181</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">13,192</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">18,733</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(13,192</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(18,713</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income, net</font></p></td>
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,900</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,752</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(10,292</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(14,961</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in unrealized gains and losses on available-for-sale securities</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(173</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(339</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Comprehensive loss</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(10,465</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(15,300</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share, basic and diluted</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(0.11</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(0.16</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average shares outstanding used in computing net loss per share, basic and diluted</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96,486,480</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">94,227,313</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
   <hr style="page-break-after:always;"></div>
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img41264513_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img41264513_0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $W R # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8$)_4FOHL^C&CAJ=*"LK_DCYO()2K8JI5F[NV_S/1J***^'/O HHHH ****
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M_H?7<-1_BR]/U%HHHKXP^V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/[5;P_+J>MD.*]CB?9/:?Y]#]$J***_/#]'"BBB@ HHHH **** "OG;_ (*
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M@R21L,JRD=000:MU^5R;;;EN?K$4DDH[!1112*"BBB@ HHHH **** "BBB@
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MY(O5W;;/@,7URJ@"YF  P )6&/UI?[0NO^?J?_OZW^-?L[_PQA\$O^B<Z/\
M]\O_ /%4?\,8?!+_ *)SH_\ WR__ ,57A_ZP8?\ D?X?YGN_ZN8C^=?C_D?C
M%_:%U_S]3_\ ?UO\:/[0NO\ GZG_ ._K?XU^SO\ PQA\$O\ HG.C_P#?+_\
MQ5'_  QA\$O^B<Z/_P!\O_\ %4?ZP8?^1_A_F'^KF(_G7X_Y'XO27$L^!+-)
M* > [EOYU'7[2_\ #&'P2_Z)SH__ 'R__P 57YE_ME?!2V^!?QQU/2-+MFMO
M#M_$FHZ6A)8)$^0T8)Y.UU<#)SC;FO0P6;4<94]E!-/S/.QV45L#3]K-IK;0
M\.KL?@_\1KKX1_$_PUXPM-S/I-XLTL:GF6$_++'_ ,"C9Q^-<=17L3BIQ<9;
M,\6$G3DIQW1_0%I.J6NN:59ZE8S+<65Y"EQ!,G1XW4,K#V((-7*^3/\ @G!\
M7/\ A/?@>?#5Y/YFJ^%)OL>&.6:T?+0-]!AX_P#MF*^LZ_),10>&K2I2Z,_8
ML-76)HQK1ZH****YCI"BBB@ HHHH *^=O^"@'_)I_C7_ 'K+_P!+(:^B:^=?
M^"@7_)I_C3_>LO\ TKAKMP/^]4O\2_,X,?\ [I5_PO\ (_'NBBBOUH_(3[P_
MX)1?\C7\1O\ KRLO_1DU?H]7YP_\$H?^1N^(O_7C9?\ HR6OT>K\SSG_ 'V?
MR_)'ZADG^XP^?YL2OA7_ (**?LMKXATF?XJ>%[,#5K"/_B>6T*\W-NHP+@ =
M7C'WO5!G^#G[KJ.:%+B-XI$62-P59&&0P/!!'<5Y^%Q,\)556'3\4>CB\+#&
M472GU_!G\^M%?1_[;?[,[_ /XB'4-(MV'@K79&EL&4$K:2]7MB>V.J>J\<E3
M7SA7ZK0K0Q%.-6F]&?DV(H3PU65*HM4?<?\ P3Y_:R_X1'4K;X8>+KW;HEY)
MMT2]G;BTF8_\>[$](W)^7^ZQQT;C]*J_GSK]2_V"_P!K/_A;&@Q^!/%5WN\9
M:7#_ *-=3-\VIVRC[V>\J#&[NPPW]['R&=9;:^*I+_$OU_S^\^QR/,N:V%K/
M7H_T_P ON/L*BBBOCC[0**** "BBB@ HHHH **** "BBB@ HHHH ^7?VMOV*
M=&^.UC<^(/#L<&C>/HDW"XQLAU' XCGQ_%V$G4< Y'3\I/$7A[4_">NWVC:S
M8S:;JMC*8+FTN%VO$XZ@C^1Z$$$5^_M?(O[?'[+,/Q8\'3^-O#UF!XRT. O*
MD2_-J-JH):,XZR(,LAZG!7N,?4Y3FDJ,EAZS]U[/M_P/R/D\XRJ-:+Q%%6DM
MUW_X/YGY5T49RN1THK[X_/C[M_X):_%*2P\4^)_A]=2_Z+?P#5K)&/"S1[4E
M ]V0H?\ MF:_2&OQ8_8W\1R>%_VGOA[=(Y07&H_87YP"LZ-%@_BX_*OVFK\Z
MSVBJ>*YU]I7_ $/TG(*SJ83D?V7;Y;BT445\Z?2!1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5\Y_MC?M66?[._A$6.F/%=^.=5C
M8:?:M\RVR=#<RC^Z#G:#]YACH&QVG[2'[06B?LZ_#^;7=2VW>IS[H=+TM7P]
MW/CI[(O!9NP]R ?QJ\?^/M<^)_C#4_$_B.]:_P!7U"7S)93PJCHJ(/X448 7
ML!7T64Y;]:E[6JO<7X_\#N?-9QF?U2'L:3]]_@O\^QDZKJE[KFJ7>I:C=37V
MH7DK3W%S.^Z261CEF8GJ2352BBOT5*VB/S=MMW84444 %%%% !7TA^Q[^R+J
M'[0_B :MJZ36'@+3Y<75TN5>]D&";>$_^A./N@XZGC-_9+_93U7]H[Q5YUUY
MVG>"M.E U'4E&#*W!^SPGNY&,GH@.3R0#^O7A?POI7@KP]8:'H=C#INDV,0@
MM[6!<)&H[>Y[DGDDDGFOF,VS189>QHOWWN^W_!/J<HRKZRU7K+W%LN__  "?
M0M"T_P ,Z/9Z3I-G#I^FV<2P6]K;H%CB11@* *OT45\!J]6?H:22L@HI*\:^
M+7QA%AYVB:#-FZY2XO8SD1>JH?[WJ>WUZ>3F69X?*J#Q&(>G1=6^R%*2BKLM
M?%GXP+HGG:-H<H?4?NSW2\BW_P!E?5_Y?6OG]F+LS,S.[')9CDD]R32=3D\D
M\DFDK^=<VS?$9Q7]M6=DMET2_P ^[Z^ED<4I.3N%%%%>&2>H_L[KN\;73?W;
M%_\ T-*^C:^>/V<USXNU)O[ME_.1:^AZ_H'@M6RB+[RE^9V4OA"BBBONC4**
M** "BBB@ K\8_P!M#XM?\+?_ &@/$-];S^=I&EM_9&G[3E3'"2'<?[TAD;/H
M17Z<?M;?%S_A3'P'\2:Y!+Y6JW$7]GZ;S@_:9LJK#_<&Y_\ @%?BKT[Y]R:^
MRX?PVLL1+T7ZGQ7$6*TCAH^K_0U/"_AN^\9>)=*T#2X_-U'5+J*SMT]9)&"K
M^&3D^PK]V?A]X+L?ASX'T+PQIJ[;'2;.*TCXQNV* 6/NQR3[DU^:G_!,_P"$
M_P#PF'Q@OO&-Y#OT_P +V_[AF'!NY@RI]=L8D/L2IK]3*Y\_Q'M*T:"VCOZO
M_@?F='#V&]G1E7>\MO1?\'\@HHHKY4^M"BBB@ KXX_X*9?"G_A+/A#8^,;2'
M??\ A>YS,RCDVDQ5'_[Y<1-[#=7V/6/XN\,V/C3POJ^@:G'YVGZG:2V<Z>J2
M*5/XX-=6%KO#5X55T?\ PYR8N@L50G1?5?CT/P)HK<\=>#[[X>^--<\,ZD,7
MVDWDMG*<8#%&(##V88(]B*PZ_7(R4DFMF?CTHN+<7NCZ$_85^+H^$_[06C"Z
MF\K1_$'_ !)[S<<*ID8>2Y^D@49[!FK]B:_GS5V1E9&*.IRK*<$$="/>OVU_
M9=^+0^-7P/\ #7B620/J9@^R:B >5NHODD)]-Q <>SBOB>(,-:4<1'KH_P!#
M[CAW%7C+#2Z:K]3UBBBBOCS[0**** "BBB@ KYS_ ."@K;?V4/&(_O260_\
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M/Z5\;5^L9?4=7"TYRWL?D684U2Q=2$=KL[[]GY7D^//PX$8R_P#PD>GX_P#
MA*_="OQF_8?\)OXN_:@\$1*NZ+3[B34Y3_=6&-F4_P#?>P?C7[,5\CQ#-.O"
M/9?J?8<.0:H3GW?Y?\.+1117RI]:%%%% !1110 4444 %%%% !1110 4444
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M^6VTNQERQ[#?($4#\:_/?]IK]JCQ)^TIX@A>]3^R/#5DY:PT6&0NJ,>/-D;
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M_#O31_NR3#^3U$?V'/@8W_-/;'\+FX'_ +4KW?\ 6'#_ ,DOP_S/!_U<Q/\
M/'\?\C\L_@'^T!XG_9Y\9#7/#TJSVTX6/4-+N"?(O(P<@-C[K#)VN.02>H)!
M_1KP'_P4>^$'BFQA;6;V^\)7[#]Y;ZA:22HK>TL08$>Y"_05V!_87^!9_P":
M?68^EY=?_':9_P ,*? OK_PK^U_\#;K_ ..UY6+QV78Q\U2$E+NK?YGJX/ Y
ME@5R4YQ<>SO_ )'4>#?VHOA3\0->M-$\/^.-+U'5KLE;>S5F224@$D*&49.
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MZVWK<H/R3_Z]>R5_2'"JMDU#T?\ Z4SMI_"@HHHKZLT"BBDH 6BBB@ HHHH
M**** "BDS2T %%%% !1110 44E+0 4444 %%%% !1124 +1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFU7%U<1A\1\3?.D^SW7HM+>IC3E>Z9T%%%%?I9N%%%% !1110 4444 %%%%
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MKB_^%R>#?^@W'_WZD_\ B:/^%R>#?^@W'_WZD_\ B:]O^ULN_P"@B'_@4?\
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MOQ]U9+'P(UJ6 EO9TC5>Y"G>Q_\ '1^=?<9Y.$,LQ#GMR2_%67XFL_A9YC\
M[5Y_B%'(H^6&UE=OQPH_4U],5Y3\ O![Z/H<VL7,>RXU''E*PP5A'0_\".3]
M *]6KR>$\'/!Y7#VBLYMRMZ[?@DQ4U:(4445]D:'D'[2%WY?AW2K?/\ K+LN
M?^ H?_BJ\@\7>%)/#/\ 93MN:#4+**Z1CV8J-Z_@3^1%>C?M+76Z\T.U!^[%
M-)CZE0/Y&NM^)O@S^V_AK;+"FZ\TN!)HL#DA4 =?Q4?F!7XYG.7O-L=F#AK*
ME&%ONNU\U?YV.:4>9LU/A'XN_P"$M\'V[3/NOK/_ $>XYY) ^5OQ&#]<UV]?
M+OP9\7?\(OXOACE?;8ZABWEST5B?D;\"<?1C7U%7VW#&:?VGE\7-WG#W7\MG
M\U^-S6G+FB%%%%?6FAR?Q.\5CP?X1O+M&VW<@\BV'?S&R ?P&3^%?.VK^#WT
MGP'H^M3AOM&H7+XW'I%M^7\20Q_$5WOQ$GD^)7Q0L/#-LY-C9-MF9>@/65OP
M "CWKHOC_I\47@&R$2!([6[C5%7HJ[&4#^5?DV=4WG"QF*_Y=T(\L?.5TYOY
M;'/+WKOL5_V;[KS/#NK6V?\ 578?_OI!_P#$FO7J\)_9MN]M]KMKG[T<4H'T
M+#^HKW:OK.%:GM,GH/M=?=)HTI_"@HHHKZTT"O%?CYJDNK:GHGA:T;=-<2++
M(H_O,=D8/YL?RKVAF"*68X4#))[5X-\/V/Q ^,6H:ZXWVMGNEBW=,?<B'Y9;
M\*^/XDJ.K2I9=!^]7DE_VZM9/[C.?2/<V/CEX.BM_!>E7-HF!I.V X'_ "R(
M"\_\""_F:SOV<_$GESZCH4K\./M4 )[C"N!_XZ?P->Q^(-(BU[1+[3IAF.ZA
M:(^V1P?P.#^%?)_AO5;CP3XOM;N0%);&XV3ITRH)60?EFOEL\2R3.\/F,%:$
MM)?+1_\ DK5O0SE[LE(^P:*9#*D\22QL'C=0RL.A!Y!I]?K"=]4= 4444P"B
MBB@ HHHH **** "BBB@ HHHH **** "OSA_;^_:_&O3WOPN\%7V=-B8Q:[J5
MN_%PX/-JC#^ '[Y'4C;T#9]+_;S_ &P/^%<Z;<_#SP;>X\5WD6W4K^!N=-A8
M?<4CI,X/U53GJ5K\Q/I7V.399S6Q59>B_7_+[SXK.LTY;X6B_5_I_G]P4445
M]L?#A1110 4444 =-\.OB1XB^$_BNV\2>%M0_LS6+<,L=QY*2C:PPRE7!!!'
M!K[>^$G_  5)*^39?$CPSGHK:MH/\W@<_F5?Z+7Y]T5P8G X?%_Q8Z]^IZ&%
MQ^(P?\*6G;H?NE\,_CIX#^,5F)_"/B>QU=PNY[5)-ES'_OPMAU_$8KO*_GXL
M;VXTR\AN[.XFL[N%MT=Q;R&.1#ZJP((/TKZ8^$O_  4,^*?PW\FTUBZA\;Z2
MF!Y.KY%R%_V;A?F)]W#U\KB>'YQ][#ROY/?[_P#ACZS"\14Y>[B(V?=;?=_P
MY^M]%?,?PE_X*#?"OXE&&TU._D\%ZO)@?9]:PL#-Z+<#Y,?[VT^U?2MI>0:A
M;17%K-'<V\B[HYH7#(X/<$<$5\Q6P]7#RY:L6CZFCB*6(CS4I)HGHHHK Z"K
MJ&F6FJ0F*\M8;N+^Y-&''Y&N'UKX&>%M6W-#;2Z9*?XK20A?^^3D5Z%17GXK
M+\)C5;$TE+U7Z[B:3W/G[6_V==4M=SZ7J5O?+VCN%,3_ )C(_E7 ZUX#\0^'
M=QO](N8HUZRHGF)_WTN17U_17QF+X(RZO=T&Z;^]?<]?Q,G2CT/B'<#17U[K
M?@'P]XBR;_2;:60_\M538_\ WTN#7 ZU^SGIEQN?2]2N+%^T<X$J?GP?U-?%
M8O@C,:-W0DJB^Y_<]/Q,G2ET/ **] UKX'^*=)W-#;1:G$/XK63YO^^6P?RS
M7$7^G7>ES&&]M9K.0?P3QE#^M?&8K+\7@G;$TG'U6GW[&;36Y6HHHKSR0HHH
MH ^F/@&NWX=P'^]<3'_Q[']*]&K@/@6NWX;Z>?[TDQ_\B-7?U_3^1KERO#+^
MY'\D=\?A04445[A04444 ?,OQZ_Y*+/_ ->T/\C7K7PNU :7\)])N3;W%T$1
M_P!U:QF21OWK#A1UKR7X]?\ )19_^O:'^1KV7X-G_BVNB?[DG_HQJ_)\D3?$
M>-479VE_Z4CGC\;"Z\>ZE,NS2O"6KW4[< WB+;1CZECG]*Y^/X7ZOXTUB/5/
M&MY&T4?^JTJS8^6@]"W\\<GUKU6BOO*V5QQ;7URHZD5KRZ*/S2U?HVUY&W+?
M<BMK:*SMXX(8UBAC4*D:#"J!T %2T45[:2BK(H*^<_VBO^1VL_\ KQ7_ -#>
MOHROG3]HG_D=;/\ Z\4_]#>OAN-/^13+_%'\S*K\)TGP:\!^'_$7@M+S4=+@
MN[DW$B&20'. 1@=:[K_A4_A#_H VOY'_ !K$^ '_ "3U/^OJ;^8KTBNW(\OP
M=3+,/.=&+;C&[<5V]!Q2Y4<E_P *G\(?] &U_(_XT?\ "I_"'_0!M?R/^-=;
M17M_V9@?^?$/_ 5_D7RKL<E_PJ?PA_T ;7\C_C7SM\3-+M-%\=:K964"VUK$
MZ!(DZ+E%)Q^)-?6U?*?QA_Y*1K7^_'_Z+2OSWC;!X;#X"G*C3C%\ZV27V9=C
M"JDEH?0?PO\ ^2>Z!_UZ)_*NIKEOA=_R3WP__P!>B5U-?H>6_P"Y4/\ !'\D
M;QV04450US5HM!T>]U&<XBMHFE;WP,X_'^M=TYQIQ<Y.R6HSPKXK79\<?%#3
M] BD_P!'MW2V8YX#,0TA_!<#\*]\AEMK>%(HY(UC10JJ&& !T%?.'PT\!CXH
M:EK%_JMQ/#$K[V>$@,\KDL1D@\ ?S%>@?\,YZ!_T$-2_[[3_ .(K\TR2MF-1
MU\RHX=35:5TW/E]U:)6L]C"/-J[;G:^-M)M_%'A74M-\V,R31'R_F'$@Y4_F
M!7S'X$\0-X4\7:=J+$I''+Y<X_Z9M\K?EG/X5[/_ ,,YZ!_T$=2_[[3_ .)K
MR+XE>"QX'\3/I\;R36DD:RP22XW,IX(./0@_I7C\41S",Z.9U*"INFTKJ7-U
MNKZ*UG?[R:E])6/K)6#J&4Y!&013JX?X.^)O^$D\#V?F/NNK/_19<GGY0-I_
M%=OZUW%?K6#Q4,;AX8BGM))_>="=U<****[!GQEJTGD^)+Z3&=E[(V/7$A-?
M0FF_'[PG>1J9Y[BQD(Y2:$M@_5<U\_:D WBBZ!&0;]P0?^NIKZV/A;16ZZ18
M'ZVR?X5^+\)T\=*KB7@ZD8I-74HMW^*VS5CEIWN[')WOQT\(6L+/%?R7C@<1
MP0/D_F /UKC] L9_CAXH.LZF%@T#3F\N*P#Y9SP<-CUX)/?H.YKMO'GPMTOQ
M-H,T-C96MAJ$?[RWFAB6/+#^%L#D'I[=:\%\%>+;_P"''B9I7BD"JWD7MFW!
M8 \C_>!Z?_7KTLYQF+PV-H4<XM+#-W]U-)M?S7;;L[.U]?/8J3::YMCZR5%C
M5550JJ,!5& !Z4ZJFE:I;:UI]O?6<JSVLZ!XY%[@_P!:MU^IPE&45*+NF= 4
M4458'SM\>)O[0^(VG6@YV00QX]VD;_$5]#[1LVX^7&,5\Y>-&_M;X[PP]0M[
M:P_D$)_K7T=7PG#S]KCLPK=YV_\  ;HRAO)GR9\3/"I\'^,+RS12MI(?M%L?
M]ACT'^Z<C\*^@_A7XN'C#PA:SRONO;?_ $>Y]=RC[WXC!_$UB?';PB==\+?V
ME!'NO--)DX'+1'[X_#AOP->7_!/Q=_PC?BY+69]MCJ6('R>%D_@;\R1_P*OF
MJ#_U;X@=%Z4:VW97>GW/3T=S-?NYVZ,^G*Y_QUXFC\(^%[[4VP98TVPJ?XI#
MPH_/GZ UT%>&_%R^G\<>.M*\(6#GRXG!G9>@=ADD_P"ZF3_P*OT+.\=+ 8.4
MJ6M27NP7>3T7W;_(VD[(UO@!X8D@TV\\17F7NM08K&[]3&#EF_X$V?\ OD5O
M_'"U^T?#C46QGRGBD_*11_6NTT^P@TNQM[.V3R[>"-8XU'90,"N?^*%M]J^'
MNO1]3]E9_P#OGYOZ5QRRV."R.I@HZM0E?S;3N_FQ<MHV/&OV>;KR/'%Q#G_7
MV3C\0RG_ !KZ.KY8^"UU]E^)&E9.!*)(OS1OZ@5]3UY'!%7GRMQ_EDU^"?ZD
MTOA"BBBOT$V.)^,'B+_A'? M\T;[;B['V6+'7+<,?P7<:P?@#H\6D^#Y+Z1D
M2;4)BXRPR(U^51^>X_C7)_'35)?$?C32_#MH=Y@VJ5'_ #VE(Q^2X_,UTZ_L
MYZ%M&[4=1+8Y(9 /_0:_-I5L7C,\J8C"TE4C07(KRY5S/=[/7=&-VY770]4^
MU0_\]H_^^A7S/\<-#32?'$US"5,&H(+@;3G#_=<?F ?^!5Z-_P ,YZ!_T$-2
M_P"^T_\ B*YOX@_!"Q\,^%[K5-,NKNXEMB'DCG92#'G#$84<C.?P-9\1TLRS
M' 2C5PJBH>]=3NU;?3E5]+BGS26QW7P1\2?V]X)@@D?=<Z>?LSY/.T<H?^^<
M#\#7H-?-/P)\2?V+XR%C(^VWU)/)Y/'F#E#_ .A#\:^E:^@X7S#Z_EE-R=Y0
M]U_+;\+%TY7B+1117UIH%%%% !1110 4444 %%%% !1110 5\V_ME?M86?[/
M?A/^S-(DBNO'6J1'[#;G#"TC.0;F0>@.0JG[S#T#5VW[2O[1.B?LY^ 9=:O]
MMYK%UNATK2]V&NIL=3W$:Y!9NPP.I /XU^.O'&M_$KQ;J?B7Q%>MJ&KZA*99
MIFX [!5'\*J, *.@ %?1Y3EOUJ7MJJ]Q?C_P._W'S.<9HL)'V-)^^_P_X/8R
MM2U*[UC4+J_O[F6\OKJ5IY[F=BSRR,269B>I))/XU6HHK]$2ML?G&^K"BBB@
M HHHH **** "BBB@ HHHH .M=_\ "_X]>/\ X-W*R>$?$]]I<&[<UCO\VU?_
M 'H7RGX@ ^]<!143IQJ1Y9JZ\RX5)TY<T'9^1^AGPE_X*E02>39?$?PTT#<*
M=6T++)]6@<Y'_ 6/TK[+^&WQJ\#_ !>L!=>$?$MAK2[=SP0R;9X_]^)L.OX@
M5^%%6-.U&[T>^AO;"ZGL;V%MT5S:RM'*A]592"#]*^=Q.18>KK2?*_O1])AL
M_P 11LJRYU]S/Z!:6OR7^$O_  45^*'P]\FUUZ6#QUI2X!34SY=TH_V9U&2?
M=U:OM3X2_M_?"GXGF"TO-3?P=K$F!]DUS$<9;T6<'RS_ ,"*D^E?*XG*<5AM
M7'F7=:_\$^LPV;X3$Z*7*^ST_P" ?2E%0V]Q#=PQS02I-#( R21L&5@>A!'4
M5-7CGM!1110 5!>6-MJ$)BNK>*YB/5)D#+^1J>BIE%25FM .!UKX(^%=8W,E
MDVG2G^.S<H/^^3E?TK@=:_9ROX-SZ5JD-TO:.Z0QM]-PR/T%>^45\UB^&LJQ
MEW.BD^\?=_+3[T9NG%]#Y%UKX=^)/#^YKW2+@1KUEA7S4_-<_K7.=R.XZBOM
MVL/6O!.@^(@?[0TJVN7/_+0H%?\ [Z'/ZU\7B^ X[X2M\I+]5_D9NCV9A?!1
M=OPUTGW\T_\ D1J[FL[0=#M/#>DP:;8HT=K!D(K,6(R2>I]R:T:_3,OH2PN$
MHT)[QC%/U22-XJR2"BBBN\84444 ?,GQX.?B-<_]>T/\C7LOP9/_ !;71?\
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MM6BC+,GI93%T\-4ER-WL[-7^Z_XBC%1V"FR1K*C(RAD88*GH1Z4ZBO>+/,?
M?PC7PEXTU/5'9'M%RNGH#ED5N6SZ$#Y1[9KTZBBO/P. P^74G1PT;1;;^;_J
MR\A)*.B"F2%@C% &;' )P"?K3Z*] 9\UZC\#?%UQ>W,XMK-O.E:3:ER,#<2<
M<@>M>B>"6\>^%]+@TV^T*WU.V@79%*E\B2*HZ*<Y! _"O4**^0P?#.&R^LZ^
M%JSC)[ZQU]4XLS5-)W1RTVO>)?*S!X5S(1P)=0B4 ^^ :\G\6?#/Q[XVUA]1
MU"*R1\;(X5N?DC3^ZO'Z]Z^@:*[<?DM/,X*GB:TW%=+Q2_".HW'FT;.#^'L/
MB7P]H^GZ-J.BP^3;CR_MD%VI 3D@E2,Y^E=Y117K83#+"4HT5)R4597MLM+:
M)%)6T"BBBNP9Q/Q9\,ZAXN\+_P!G:=:PSSM,LF^:79Y>WN.#DGD?C7D.G?!O
MQQH^H07ME%;PW4#AXY$NEX/]1[5]*45\KF/#F$S+$K%5924U9*S2M;;H9R@I
M.[.2T'6/%DGD0ZOX>@B8D+)<VUZA0#NVPC/X9-=92T5]#0HRHPY95'/S=K_@
MD6@HHHKI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
(% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>spry-20240509.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-05-09T12:33:28.2596+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://ars-pharma.com/20240509" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:spry="http://ars-pharma.com/20240509" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://ars-pharma.com/20240509/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://ars-pharma.com/20240509/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="spry-20240509.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20240509/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm139729066953328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>May 09, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001671858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  09,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARS Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-1489190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11682 El Camino Real<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">771-9307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SPRY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>7
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MY?.J>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^
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M-_=%KLWC":[?#'!X=/X!4$L#!!0    ( !*!J5AED'F2&0$  ,\#   3
M6T-O;G1E;G1?5'EP97-=+GAM;*V334[#,!"%KQ)E6R4N+%B@IAM@"UUP 6-/
M&JO^DV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/$;#HG?78E!U1?!0"50=.8ATB
M>*ZT(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4Z]4SM')OJ7CI>1M-\$V9P&)9
M/(W"S&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N6%"*JX1<^1UPZGL[0$I&0[&1
MB5ZE8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC JFQ R!GZ]%T,4TFGC",S[O9
M_,%F"LC*30H1.;$$?\>=(\G=560C2&2FKW@ALO7L^T%.6X.^D<WC_0QI-^2!
M8ECFS_A[QA?_&\[Q$<+NOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ $H&I
M6 =!36*!    L0   !               ( !     &1O8U!R;W!S+V%P<"YX
M;6Q02P$"% ,4    "  2@:E8$8])Z>\    K @  $0              @ &O
M    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  2@:E8F5R<(Q &  "<
M)P  $P              @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4
M Q0    ( !*!J5CR 8"/A 0  ,X1   8              " @0X(  !X;"]W
M;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  2@:E8GZ ;\+$"  #B
M#   #0              @ '(#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    (
M !*!J5B7BKL<P    !,"   +              "  :0/  !?<F5L<R\N<F5L
M<U!+ 0(4 Q0    ( !*!J5@<.&7J/P$  #P"   /              "  8T0
M  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  2@:E8)!Z;HJT   #X 0
M&@              @ 'Y$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"% ,4    "  2@:E899!YDAD!  #/ P  $P              @ '>$@
I6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"   H%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="spry-20240509.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20240509/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="spry-20240509.htm">spry-20240509.htm</File>
    <File>spry-20240509.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "spry-20240509.htm": {
   "nsprefix": "spry",
   "nsuri": "http://ars-pharma.com/20240509",
   "dts": {
    "inline": {
     "local": [
      "spry-20240509.htm"
     ]
    },
    "schema": {
     "local": [
      "spry-20240509.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://ars-pharma.com/20240509/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_9397e41a-9e33-41a3-a2ab-4dca433c08ae",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20240509.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_9397e41a-9e33-41a3-a2ab-4dca433c08ae",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20240509.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://ars-pharma.com/20240509/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://ars-pharma.com/20240509/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://ars-pharma.com/20240509/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://ars-pharma.com/20240509/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://ars-pharma.com/20240509/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://ars-pharma.com/20240509/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://ars-pharma.com/20240509/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://ars-pharma.com/20240509/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://ars-pharma.com/20240509/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://ars-pharma.com/20240509/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://ars-pharma.com/20240509/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://ars-pharma.com/20240509/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://ars-pharma.com/20240509/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://ars-pharma.com/20240509/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://ars-pharma.com/20240509/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://ars-pharma.com/20240509/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://ars-pharma.com/20240509/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://ars-pharma.com/20240509/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://ars-pharma.com/20240509/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://ars-pharma.com/20240509/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://ars-pharma.com/20240509/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://ars-pharma.com/20240509/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://ars-pharma.com/20240509/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://ars-pharma.com/20240509/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0000950170-24-056934-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-056934-xbrl.zip
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MZ7LDOX*^XYA'T01]%C&)J2 1ZE6='L$H:0.=1A'JRJ\RU.493Z\X:Q1M]G-
M!Z DSCX<S(S\VFPDZ653]WV_.99U#HI*K7&01DQ,Z\I'5=/0-*=9%,Y5S1=6
MM8NJ^6Q5,3> V=IF$]"8 VB\J@^(_W%/=5D<D&Q:?7RG_AQ\LK2J*L;+VM7E
M,.2,RPFOJL=)? X3GPJZ^#.6I\U\,N1-J(CCHN9T5)E8-": 0&_^\?5+C_;Y
M@.#;H#-^"_L9IXW+Y*H)!?"M84XAR1++T-W[L%K4J#[(ANED6IND&1[V23H@
MBFXEH6FVYM^@*<?0\5SCU4!NL-3,4Q)G80*M2&J42 0*]["IS[2S>(#W-6(8
M6#.P[E2-C/)T*91^$TH//OZ$3OJ<,/@?G>0BC_A'#_]VTBQ^RI<#GA/%NIC_
M-1)7'P[:29P#0^,+F+T#1(NG#P<Y'^=-Q1!-V6BS;/4D2-@$9?DDXA\.!B2]
M%'$+D5&>_$T,ADD*,Y@?#PF34J:%O.'X^$#URL15]1$3V3 B$TE1'$I/Q+@E
MV^9I\5,PQF/U\X;DD& ?#C[_1W,-TR:FAZGE.]C270M[H:YAXOK4(1;Q+8FJ
MF QD+URTSF( >](&<%(2=6+&Q[_Q20GB.._R$(#_CV_Z+K=T@GUNFM H,3$Q
M2( M1HEEFE3S"#_XJ &M.J[NV=Y)<VYHBT?*+&I:I@L$0+B!+=\EF-@:Q8ZG
MA;YC4>YH<R,]!9'*I%C]')'+E4:("KKY< "$U@K%F#,<D@@DPT?UWYU1-^=Q
MG?*0I[ \\.SCB902K4PQ)8P *:G1DKS]X2"#28XDAZIW_50.4'(3KMBF,<X8
M$(QJ?K9-]9@EHU0]*2G8*J%4*'OL/)2?<C6SU9-@\CD4/$5JV'PAM[8[O\W/
MX^V//U:OYEL? L(25CV!C$ISN9)]O%G(JN]NRJ;#9$NJ5B75<]5)<PXU%1ZG
MB&O.,$L3>&K*6S0B&2QL *L4'?@R34;#@UML*KFTXDT<\3!OZ2(^OA8L[[><
MA@V_JT*U[JI2P/@,ZU;E>3)L:>J+@8AQGZOJQ8L@&>-,_)]D_R!)8: 8WLAF
MAE4C(< FJ_"6K@WSXV)P19/'JBPD Q%-6A=BP#.EE723 8FKBD&2Y\D ZDH$
M81*)R[@E@9%]9$,25]U<]T7.,;RAO#5,.;Y.R?!XIF\#^KZW.^BKP$TH<ER*
M1>CD'S_KCG9\TI1]P20,RXEX#'S60UTNAY!"YSR]#2--HB1M_:RIO^/E$%\7
M,Q0D$9M%@;<B"GX_[UR<?4*]B].+LUZ%B1T8%YJ=E6W2VT[-1N^L_7NW<]$Y
MZZ'3\T_H[(_VOT[/?SU#[6]?OW9ZO<ZW\WJ*-@3UJC+CWR3K@T3,D_@(?6JT
M&V#.V):_A6E9=8!/G1;UO$LSLRH]?O[6_8H63<03VCY8K ,23[-=D[O8I$3'
MENES'+C4QC0(F>98OL=,<S55[T9OK*QQI;OO!$*5M5'2TFV5<V^ET,Z1^ZI\
M#BM%]^S\ G7/OG_K7NRQ 'H=Z\+W49J-P&)&>8)ZA>J.=!,E*=+M0_:^GI\7
MACH)4=[G<FI&J<@%?',VIGT27W+I*450K/NFM<?3M'G!]@0@EJR;ML.)Y9@4
M&[9I8XM8&O9<U\&Z9EK,]3W'-\FFULWORNP^*XSQ>1\*@S=X +WTY6>8D0F>
M<))B'N\&;7XE$^0?*<?X PONFV)9%60 QNQRZ8U$A]4S3%T$#)PC?B6C%ZDJ
MYGLM8[?)O,9#OHIES!L8EN,0!QM,NFA#S\9!:.J8:Z%N&Y9)+)NOR[R%6[?+
M+T4F/>;Y.91LE/@>!'[9#)YV>^B[BB50/LH%)5$9EWHVE7CEH>_W O\@)RR!
M^O!L3& AE[0EA40ZI2E$,I0-.96.889$C$2>(5CZ06:DVY 9JP(P.VT_(1GS
M(4'$YQV_A:]7>7]+EZP<F/30PL3(ZC@BDV14A@U*A["N:0WM[]4' %U$AAEO
M97Q(4A"IU0P7GF+5M@KTR!&D5?=7(A.!B(!96U4#52VHQJ:>6M6A:?W]6(6:
M%I;J]Q6:QD8^/6GFZ1T8K@$!.$@Y^=%2_V+Y8O'\+@!MWF&N:>:,DUW-2O7R
MBJ=*7I1,,A",17Q:M>*C6RVDI=^]>+O8Q^X]MXO]"7[SG&T.8\68:XS5-%;3
MV.Y@[&W1V,(%I(R.JA7^91:35<AV <:>3RE<;%H8)&0L# SL>";#ENG)G K+
MP<P(/6YQZG"';<:T (T]2<$^5&DXO1S4G78RBO-TTD[8O)= I@;)L'_.AVER
M)=O9B'M@J7'+(W)-4OX(@W]'!=_SA_SW:*W80::CMJNYA(88N,O"EJ];.)"/
MML5\XAFZ'YC!9ICNLX@X]!WP=(L,I&DZAM'93LU!-0<]#P>9S/8M.PBQKZM4
M0,HQ,7T/<]WS7<OD.C4WY!&[(.-.F<Q&U=*U=7;R=*Q;GJ_[VE/XZ3XUR7LQ
M+0GJ;X/6-J6W;LYMMM07IC0=&7Q,\CY/T9^C5&1,J*CD \[!-8#4X=-G!3,)
MD9C5[][OE #;7^.GYL%-\& [&0Q$EKTNEI.J'2H6HYK;:F[;'6[K='OH;#",
MD@E/7Q&_S6N!Z#QI+&:[J2(&/V0<:$?LC0V$TN]PSG['QFRM8=\;XFIH]X;
M+*]A>:\\T%7;Q37*:BK;Y3C$EO2-+6>FK#DI&Q[PO;K$$@>404V?Z28V33/
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M94@O^% WP'H\--[?[\>;[;2!;F-U$>QS_#W+V/+LAJ0X;D'Y(,LS&I1E?&L
M<GQ3%-Q<%P(&.E/FNJS>KNSXRJ=9%'(8G3IV0^EA@!M&)M.CFA@,ZDB:]F!<
M1^6Q;') ESR&936:OS0'1=#]"!0[23S9"(1?,>(CF6G A\7UV0H!@70$*$DH
MCZ'@N9QK  H&6EZO36^PD-UJ[=F6ZU5TO%6/0'GBU00JT&*YQNS?38[+(_9A
M &O>MPUCS4T7NG;OV17:(P^NV*,\C-W<'?;H<)$2\D 2^N[$$/<<HS=VACIQ
M6.[!JZ2T6ARSM;2VQXP ;2ZBY^RC,_N0O7\#BO'Z^%W5+?%Z]@BZ]]Z2\\ M
M.I[7\.M;=%Y)IDN='%13V>O:C/5V3F$N%:M7E,Q>'"2[!\)NFSM,UC@$ RU6
M@6N&VPQY?N(93<7P]DW0CQ*5M@IUOY"TW."2M0<KEL(8S+LL^G!@'-38V]RM
M>0W]-1#QCIYA),,'M=JZ>4U_,2:>"3B"^JE,;<N&Z03SL>__1V_T\\%RJI%'
MN2U"@FJ;<5K&'EKJW*I(Q/R^,[&R#'7+R"M3X9:9X/ 4;^0-BH!](>%Z'7OC
MM[_NUQ*F:]9.F2#[A;TMVF^OG.[:"<"+OLM0?$>:@82JR],^D9R@SR+BZ) /
M LYDEI+,)BA3DSJQ7#_1'[]TOR"6T)$,6KUO;"Z,M.=!CEVY9KK.@=[7E-TM
MY$#K=0;T+F8<;OI4V<ZOYZ<7OW?/>CMZ2.RC]L0]./V[F$;P?68?6;'-[:\1
MR,8BH6.5/,0%>^78*)H@2D9R?YM*L2SNMI)=!AQE@  HD#F9T&7 ^R0*JYP^
M9?66%61J\$AF#*KFR"CO)RF SMY"?O"+;B#:[^P'X][T!L-ON,Z]^1'W%EH-
MPWI"MM\NG.;_[-;\;/L+S_3?K+_OK4"_P%6T3R?[/SH,I[:T_.NT^_6T??;[
M1:=]^J5WA#KG[0<,MUD6?)-L]ZJYJ@;NJ< ]\LRB30'[!'M_&][>7>#X'?6=
M?0(MJ[4P,+3S%\:\N"C8T2G]9=):$<[;!S3</9]AOS#1S)JH*\!$31GZDES#
M2[ FC]#71J\!__;.OM3BY,TQ5@W<O@*WAB"HA4!-2C5PKP&X]6X)S 23>_GE
MSL1V7_ 0G8TY':EH\;<P%'1)_OG+QW_W-32JUX'1M0*C9?V39I"PR<>?3IK]
M?!!]_']02P,$%     @ $H&I6 >!6*3#"0  77T  !$   !S<')Y+3(P,C0P
M-3 Y+GAS9.U=6V_;-A1^WZ_@O)<6FRS;:;K&:#)X3CL82YL@2;%BPU#($FT+
MDTF-DA+[WX^41$642-FQ$TJ>TH=6E<C#[WR'E\/#B]__LEIZX Z2P,7HM-/O
M]CH (AL[+IJ?=K[<&*.;\632^>7LN_??&P8X_SCY##[#>S"R0_<.GKN![>$@
M(A"\NOGT&GS]]?H"W-@+N+3 .;:C)40A,, B#/VA:=[?WW>=F8L"[$4A+2[H
MVGAI L-(A8\)M-A[<&Z%$ P'O<$;HW=L]$YN^X/AT=%P\*X[.#YY^V.O-^SU
M<MFPOR;N?!&"5_9KP'+1LA&"GK<&'UUD(=NU/'##"_T)3)#=!2// ]<L5P"N
M80#)'72ZB<Q5X R#1(?0(G,8?K:6,/ M&YYV4DTL$AC^PB)+*U:!E=D[[IUT
M@!6&Q)U&(?R(R?(<SJS("T\[$?HWLCQWYD*'LNM!1HN0(/>9F@,%P\ GZ\VE
M)6DABI:#+/%J2KPN)G.6K&?"50A1X$X]:+!DD,0$!\: V3G)3M7-,C,+W1^E
MV7M]\^NGB\2:/+'GHG^$U+GB>D<F^SRU LB31X$QMRP_RS&S@FF<.OW 0![Q
MQ YT12T":'?G^,ZD'X2$[*,3RC3N'9O)QWQ2MP(PK8PAK2 9X%5)P92._LG)
MB1E_[9Q]!T!<2=RECTD(DKIR@>V8VXK"V/\,7J+!7AG]@7'4[U)A'8!*M:P"
MKKD?"&ZGG4!D1MX5!#<2*_U85:[4JEN5&*CJ#WLPV$-EF:5:][A"I57<A%X8
M\#>5$.0MY &"A1 .XW+9*_[2]UTTP\D;^HY9:$BP!V_7/@3LX<OU9%-W8H;6
M"B.\7)LL@WE-__K&^W#^[P@Y'U#HANL)+8X*8#@ZP*4=R/;).4J.TX%T2'!C
MC?H]]H<.&+FQ(WNTD ,2:2 G[KU9%%(0'P70N41G\;-/:$^/$OHNZ(LT<YJD
M(J-M>7;D/3[? RQEMO0EMY9H0][48HJ]M.\I&OD:SI[?QG'7-UP0.#OML,')
MX")91?[AT8)"JBH51!N4E_8C@MK6%'J,L30U UO1(<6ZQ%TSE^Z&+$,F1BPU
M'A,=.M8^%)L5C&TAJ<?:.":B^MOW,3_0_WR[(G",EY00.Q[W)T$007++$)#+
MV0QFPF.TIYVMLIAZH"?F&SD.;3?!#6TW\))<$7SG)B-F$79E<DV0;XG%7->;
M]7**/0E&\;LF4-3W=&W:#:#Y)TH*H>ZH!)DD41UF'M/'2W*+[]$F"^=2:@+Z
M!W%#VG99VXB0FPR_@02F/)U6-L>TW1++F] VN_H=KI5<%M-I!7EKK28.!4"G
M'@E)GZ/E5-HC5:?7"OH:SMV <H;B>9D2:R&95H@?5K2;H=,N1M$5;<K84<*4
M)-4$E0_32:D?D,-FW1*<\G1U=$U7F,Y^O#]=?XR=C>./F%@KW FR,:$SA;B)
MQ./@&$>TF:\K<5?GTJ0 F]1X5PN,H+(K*"71!(T--R,"+06)PF=-D I^VJ.<
MNAK<N3&^@V0T9;VB'<HH%+[K\HV@'9&X([07%II#1:<N3::W4U]",J?>V6\$
MWX<+:DK?0NIQ79Y:$^ 1K6!.'&3TK+D$HOA=*XL?74_=M922U#'*I/_0>2,<
M;!IDA+0U@^T_ FQ?=^ON#Z:W;%)>T;*S))K]'Q9UJ7![XL\R2"PIBQK3)[94
M I'QY48,-%"V<42D4^5-,_QOWC2;(VX5_6"B.V=4K&'GY()$,$@D@UAT&G"*
M<S1=+3H/#N!%IAL8UZA;571C1W.EX<Q4YD\@E@HP 5SNH>B3MU.M2@GAG1VM
MDLH B9#&HLUSK@]R.4JU(\L/@@"7U&S<>;XU@U>$W9ZHUV$"6?MD(@] BZJ^
M1I<JT@#CCN9(90%16./1Y\V@7P5I\'2_]I * [$T0,4U'K^D)=2@A"(HO)\Q
MJ% @2@6)V(/11V*<&I42H^'[V>9!%F#"F@Y>8@CM&I2C_/N9X,,*/ @$B<1#
MT$)B"]VJ2)<S=K1&MC<E$0:HM'CO8N/QY^U0AQ+JE9HG\FD3F8 *!4SJ8>A2
MY=EJ5ZAR.6H_*PFB<P&"M(!#5%!B.D%^JJ0N#8MK=#O:*Q8#8CD:/)5]0>=M
MH!=Y?NUQ1ZKCF2N3\>QU8Q^P>8KU(5:OG#Y5F+RF^/AS1<9UJ2,L&.]:\9D,
M\!>7\G=C\0IU7R-HV<KWKC'75!3@LIY]^O,4X(7 JW8-*I;S]YS#I2)!(A.D
M0@]$%]E,3K]"PD:&'<V1R0!,2&/1Y@G7![FX(V._CL>% 3LX")@\;:&OW<%+
MZKA6Y))-)D\T/4X? ),);N_Q0>A2-3UN@D+]YS#.)=(7O-A'EZV-\\P*%7<3
M[;H'@.4%> ;Z@U?3UX!+;3)RJ9M$A8%8FHZ0)-LJM6\DE<EH*E9IU'1+P",B
M[F"SB,V+IH\;2D]3F#:F,SP_-!+2TNPS@I=;'AOC"/ C=FNIMK[I4&B;\V=<
MF8W;F>I41'HJC2,O[P*J$ZKZK!K'J]A*TYB*4C[!)JTCA1TH=<*O/-?&P:MW
M;=3/O.*TF\B[;+=#_= WG($35:C:&U"_*O*3<:(&DK7T^H&KS\N)X!4+T'4J
M4'F*CJ-7K]G6SWW5V3IIOUE>XJQ?B:U.W(G:;%[^JU,MU3D\KH-TK:Q.P++3
M>1QL:<6I3J";S^PIW.,F.<;2DWP9W:55CEK]R8KS?9E'J5HEJ+]GJ3SU5QB=
ME''U.M60G@7DP,L1Z?H9+Y\0%&DNQ'/K!UQQ;E Z@)9BH$U4H;^M"OW:55"=
M,2SV+D)@K0D^8_[D8=%5S.)3^<N1<F$F2OT_Q6N3BM=;R4);SW0Q5'KC4A&!
M&);3?/%2(X^[-_AH=L.OK-GWO&Z[KU Y@%MS#OC:%)7G4K$8_7+3T__ECH.-
M7N VB^$O=[T=_MV#FP-J*L"U7%;5P N5&GS]U$'</=CPBR8/[+ZL [ZYM<'W
M[C3SAM:76\B>"_!3WX69CS$\2;3&MPB59]@+U\NP;1EJ+\SF,:'M_+3SYH3]
MNH)/%6!UY;1#'<$HH$BPSS"S/IGJ0#L# IV+A(.M]QTUG ]%("'EY;C75E[$
MV 6GH]]V.@IQ$\[+H*V\R$,UG):C=M.R(3S$67K3;I;R,2A.R7&[*5'&OC@_
M;]O-CS3,QKGY^86;4E2/<_/NA9M"$)$STW('6!6U3.EYVUH_N"I"RLEIK5<L
MQF,Y':UUALNQ8$Y):QUA10R:\]):UU<6]N:DM-;YK0JV<W):Z_EN#NUSBEKK
M )>7$#@EK?5["TL7G(_6>KOR59.4EI];[N4J5FHX.ZUU<]7+0IP:+2YONIFV
MN&.5)^![;=WD!UB3U^_-PJ_MIB]RO\F;O$E^(?CL/U!+ P04    "  2@:E8
M"PR.M\$F  #89@( #P   '-P<GDM97@Y.5\Q+FAT;>U]ZW?;MK+O]_U7X*9I
MC[,6I>AA^2&E7<=UDN[LD[0Y=KMZ[OUR%T1"$AJ28 %2MO9??V8&)$59DI^R
M]4)6F]@2'P!FYC=/#-Z-TBC\Z1_LW4CP /YE[U*9AN*G#_]3.SVM-]^]M;_"
M!6_S*][U53!A)IV$XL=7$==#&7<9SU+U?V24*)WR..TE/ AD/.RRD^2Z]XH>
M&\@Q\T-NS(^OC/!3J>+:4*LL>77C4?BDXOY:* 9IMRGCWI4,TE'WJ-Z!GXLO
MM1R.[+>O?J+'YP\JOD]5TFW0'9&,:R-A+Z\W6_!)7UW7C/PWCK&O="!T#3[!
MYR3%4P8J3O$2T6TVDK1G1V>?V:/O!CR2X:3[NXR$8;^**W:A(AX7%_95FJH(
MKDW%=5KCH1S&71HPO@3O+][CJU#I[G<-^M.[&LE4U$S"?=%-M*A=:9[8UUW9
M\?=5&/1NC.W6X<!8[.(-9%KSX4H1XQ@^7(]D7Z;,$AF?\-.[M\GSSA^IB=.7
MT9 9[?_X"GXX;+:.#CO-]O]OU/]*AJ\8#].%G^>CLE-I'B%?Y10]ZA"/_?!=
M\ZC1HSF\!69XWIGXL(A"WR3E<N+9M[<>2:MB:B]#I<5S>R*;MA\Y];.+2_9U
MQ'4$;\I2Z?/0L'_"&T)\BV'%FKS@2.VE^*JN3&'%_*5CC\5@,%G#")>-AUV(
M81;R5.D)^ZK54 MC&(\#^!QQV["/4IN4_7?&-3  :S5:A_!1S&-?\A N,EF8
MFDV:STOCUF/F?#_)OS]3O=BDGP4&5K<.*Q6NL="$+?G439; S*?#/JDW#AN5
M/\V5S0*0_?BP]R086_7"'HA$QB(9:?B;Q=R Z)M$\\D;>MI[G0W969+ $SC:
M<.S@U_=G;PA%SB\^,X"41,5&L"P&FPI^'4NXJ3]A']^?L2N9CN!*6&F9\%0$
MQ=>^BI)0T-/@2L%U.&&_^:GJYR"T'1R_IX*^ZFE?%!QDLGXD4V23@=+/H>@W
M"(M6SCM?N/X&$A6#K&;I2&GY;RNM,Y+[Y0PD-U7LPY>S'[Z[;C6:ISW#SO_Y
MY6N/_F8*@  O%-<).&Q "!FS= 24$?"F@/V=VPEJ\*)2ZI3QVJ?]58N$:^0N
MX![@D50"G#.5I0#K4M#XLF""C+'Y8KM1NA>1+B-31$O.#D9R+,P;%+M<Y$8\
M'+RTO+T$ZSGYFIGVZU:K73]B\)00\1?H[W,S(B,+&"'3('#P9&Z0%0#I_1%K
M-SUB"H\E6HTEAK_@\BER*S!H.>D#G<57G&23IRP4'!R^=*2%8!,PO$R/78DP
MK/D\H2'^&VX%$0=[&!W$&=OMC_IEG84\B^'M6R'HFR3G-S3IC%CW]4_T_P8-
M]V7C3T]1\$M8Z2Z'[4[\>4&V7C:6R[-?V?M/'W[YC=5J(/43=FI%_@44V+(A
MP4 6Q.<\]BGVZ^ 8<A/PO[OL\NO%_WWC,<[Z4B4SEY+GQ^,)"T2 5JE%&Q$E
MZDJ0><'3FI;F&\OM"ANM N4HAJ 9M<&K^R)%(Q1@+P6H0ZF*C A!;[*!5A%(
M&%PH& ]# 0SG@\O)*?< ]XX  'V5A0'"(+V9QSP934)^+6$2J0I@D36%QF!@
M_<R 0VP,RY( 1FJ',BBC8]I&Q\A70<D>4"CMAHE<WP81VA*-O;XI6E_)[_V)
MX0RD=25^@6HU1&[X.Q,&V6:W]>(&Q=#6AX)L><0,_2"98P7%,XS)N41E>AHL
M ^CY^/[, ]L+X"R4 %GX(\ <@T6=,#]4]J( OAQ;9)QB3"Q$$(K: &PXCQD^
M@+^!K)AA'<./^&8P\B9X.P G/*TZ6*/"C/@6OL4GYA8G&9:)4,#5#-Z([Z/8
MW>^31+!/!9C"O&3LAUEN;);066>_90C($J1W H#H9W"A82(V&0T]GQH9FHDR
M$@>01WDXK)+O \H.LG"KC,LU*N'<E"1[/ -^8CQ!'X"'P$\C"0N(:U_X 4C&
M_(88L)09><TB>-0(J/:IR-Z'$V^&2%5OP,9P603*3M;099AW+4BQYBZ#(4;?
M?/JM$3U >T1"HQ%1!.G00AE;'Z]"7,_JG: '0BX#=@&DY3I@G\%6 OHAN<]5
M;: H\.ZQKP N,L!8#(7F/_R&<C0UUNJLT&(HJT,%D"7)G"(I%9:&4ZM+XV-I
M)%=*A^BP $1QDE2\R='W%OH""3E+X>IPPN#"6.@Z^U,4 ==Q:3Z@EPZTJ*B)
M')3GPK,6U$FDT<DOPK3X'SS@R]D9W ;4S(W/ZMO($C96D<"J6WL[@<M@5%:T
MSS*3:EA/>.X-6QV-9+CJ_/(SNQ1_2YV9:F@ !UH C[72Y]AZ*X!\O8Q2KCXM
M(=[S_P0/X><Z^WTDP BP^A*8IO!"M!B$R =(^53P:,HI\"0%H"RNA6]U/#X2
M$3JW()! ,HT0(I".0I.>+V2^7J#-[MOS,RY+I8P,%O:Z%DAMB]6Z,)@LBGN!
M-$G()UW\=J:N3,:]OX!\<C IGDW7U$0<X+RH)ND?C+%W(STM5!N*6A]<TF\U
M/@!1[?(0%*C9EG*V122[BTB/+5>;#T$]?Y'7,P2B5H=69.]5"GHN4YYF9+@_
M5]G1D^5K(]<1W0[R:YKLK @2711!HHT>^3+<RCF:2F<;]7;[M'/2GOY!_)C%
ML*FD','8%F*82<%&Z)%4U&"^D>GVN0$;(A9S\C,=+;S[L-$ZGOXY@5>O"?$[
M]4ZKW>DT6D>=D]-&X_2T\WVY"C+&B=1H,6Z9?1[X:;5*%*JL>5Z6VFC<?.QZ
M5-HGS/1K"3[!U.2O%%3(U,P$']!X^_B^:F7F)BDKJS$^VS#KP?G%YS?@*IB,
MRG>&X(&@U8 /_/7]V994:JS162_"PRDH?6M[ 6#/AE6J,>HE\16P!:?T ^L
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M65KD=I#U#BI!M!-8H=<V@:<?HVF7+=UL-NZ1[''+LEEX:;0W8N&<P#B!>:K
MS.7>G<S<BZ^<9>+ R,WMT4"["1R[2A@]R&*>!=AZY,TC*;\)*^+X?!?Y_.6H
MNDNSO4W!4QAL7L/[8.4,_-5J>%BA=6135HF-9\;<B$,_&2A>/I/T@BBX/9-[
M# Q.I?8YITZAWHT PKV8KV/D'27L;LWW$3K].;SVS=7I2S/->:L-3JJ\NZ<H
ML=.3<Q#HYNL8>9<)NUOS?8)_?E^U35.16&.5/W+AV.]0[M6R%GI(]:F-F[4U
MFZC[L2VD/3\!?L#]6&,>BO@>'OU]EFM'0,?-&)X9J\V:[RS3+YOHZU52=3,P
M]@G2WCGR&HVCK2:[DV$GPWLMP\<-[_2XN=5D?]G@CC,('\)>ER.ETQK(192?
M0!DY:]#->!<A95\52//HV#MJ.2O0R>Z&S-?)[OUEMW/LM4].]XW<+ASX0M;?
M5RT2+JF_(NX]-=56H#-90@>Q;L;W1YF[=UYL!PX]DMP/VGBRG8JIY1TU5JB6
M[K/A9*=9QB&$0XC=0HBVUSY:H=.Y.PCQ J'-Q]BRFV^L_DYG23J[U,UXM[W?
M?0UVM%I'7NMP[U)=3G8=,;=?=MM-[WC_D@PO$*C<35ON I>HI@8U.AX#33F'
MC6[&NP8/^ZH-FJ<GCM1.;C=CODYN[V_%=1K[1FH7C7LDKWS$EJUY%,YCL3/@
MW(QW#QWV51$<-??.E7=RZXBY]7+;.;Z[3>Z.D=J%X![)*[]1F9]+H[H9N^(=
M5[QS0X^T5AC VYW2'8</#A\</J!_V';XX(*)JR[M<[:HF_'3P*-5;R%Z!"K#
ML\C6J&W6T.GB/BNQ]8JGU3KV.B=WGVNR&O[9,O7C(,-!AH.,^=+$MM<\>39[
M=;LAPQV,L*J#$3Y+3B>.RGP7M4F5_VT$=PAM?OCNNM5HGO:HX6(ZV=->KCL]
M.=>HULW7,?(N$W:WYNM.3WCBZ0GA5-^[(Q1V<'(.!]U\'2/O,F%W:[ZN9]H+
M&0!GO@^+F!J6\ G'F ]Z^]SW=2:"JE7 #F3LAUD@XR'3(N0I?)UPG4X8C^P#
MU("];ITTZ &OF\<G'EQG$N&G<BS"R=UGS^YWC'?_9KQIU9JNG?MCVB(=NLV1
M3H0W9;Y.A!^14/*:'5=FO_K2)F=>4AY)<"-*.W+B%0W/'+"Z&;L27%>"6VJA
MYK$KP77XX/#!X<.2LB>'#^L)D^YRB;X_G_UT,.QFO&O>[KZ&-MK><;/CB.TD
M=S/FZR3W 4')]NG>M<YV^RU7%62,18KIZ,*\2Q1,4,4.+MV,74S!Q12FBX;[
M6 Y?AF>V++#@0,*!A ,)]"%=W-'%'5<==W3Q1C?C'79D]S5JX>*-3G(W:+Y.
M<A\0;SQ<98_([2"VVS3[V$VS*HID&@G<]8*[7? ;&0]%[-_'H-L8EG&;#MVF
M0[?IT#&R(^RNS7=#^F!MRD:@!RWKI>MTM4^3NS<B;OM$W>2V=7*.1;=\<JZP
MYY&Z^*L6 Z&UR/M/>NQUHPX/:6+G"3;F8298(F!%1UR+'FLV//@2_[>?@'.>
MI2.E888!XRG[PK4_8NVFQUJ-UB%Y[N^%+Z(^/"+_M-UCL2KNEL9@$PR\3F6I
M2>$'['YQSR>Y8*F;\:Y%#/<U/+SZ2J&=IK<3WATBIA/>+:6WJ]%Y0GI'Q?<R
M.5N-E=B<IT=>Y_C0:QR>TA7PZV'ST#L]:J_&%)WMQ.:0WLUXU[!N7W5;L^$H
M[<1V,^;KQ-:)K0N!KKP_;Q!(W+S(0[! 95"3,?-Y(E,>.GAT,]XUF-A7A= ^
MZH 'N,*M1CM-;B>[.T3,'9#=EM=HN!:Z+KQX3XO.][,HLR<HJ'0D-/-5!'>-
M1&SD6+"#4!GSA@VYC*F3A4-.-^-= X]]U14'S=9V*XK[==AWA[UL%U6=!-^;
MVH>G^T9I%[I;@:$7B('TI;/EW(Q==R'77:AB#QXVO<[I"IM&;&B/(6<W.K1P
M:/%DM&@WO7;C85L+]@TM7%SR2:W)S!.VO^XW.._?C)TZVFMUU&JUO9.C%;9-
MVE!MY##"883#B,>>V]7PCH]66.ZX.QCAXJJKZJ%+NUZ<X>J4TC,@3*O>0H@)
M5-8/Q3K5TAK.-K_/2FR_AFH=>YV39XNIW%BU+=-1#C(<9#C(F#=JVU[SY-D<
MW^V&C-*LA1\X3&!#H.#&NV]]W;TG'<AQ.;=07-<"J7&7M0+&5F$6Q;U FB3D
MDRY^VTMX@+NV*[Z+M"_+C7[[P5^92>5@4KR7;JV).  FN<8)P!.Z);]<;PS4
M/LOZOH4%MKPT*CVDA ^%=7YJ? #@T>7A%9\8'&2%',5:T^07+_2^KN>SSF\*
MZ _$6GK?E:5/'[RX52S V<4E^SKB.H(W902[QF.?8K]>79.]68US%0<B-B)@
M\!.%3*@RZ3*%?VPO<S5@OR5"<T0PZU2?SU2F?U;&[.72'<B8I2.5&5@38"%Q
M[0L,.V%O#EJFLB,(@S7E;_9SC;*89P&\+'BQ^:\53$DMD853&DMVI#BJ+L]2
M59AU.!C4,C!VO+P&!H'*0+'+:Q'T[+N:C4:]\7UQ U PY(D172,2#N(HBD4@
M0]8^^]5<Z' LC;0'H':+!RR,"=(+CSOUD_;WN'B++5<[JGKSSDONNN"D?GIR
M^.2GK&LDM\5H3U9T0L8\0V]&1]3%Z+(S#5]?8'IEX]ZC.QKW/C8/=K)QBF1I
MS'ZDA6!?X/>181_ $ FFG:L>R1^/SP0][[*]1-=@AST.>U;4-'SWL0<;XSF,
M6:DD;-'LG"!4!>'N/-=^"H*K&GYD+N1"C$6<"08+0YT,P/$$7J$0$N-#,/HH
MM+22%-.:%F??-@.O(6NX]1G!?>TQO=7T=H+M!/O.5+_KU(G/V>F3@%_ F=J%
MF;FS0]U\=W6^CK?W8KX;<B[N]GGY>5E(/&3B.L$B$M-U*G!OQ&;?8&(OY^MX
M>R_F^P*[#FDJ$HL-\T<^<N=(M9Z*GE-]<.-F4=<&:LT+8005.6"-8"#&(E0)
MAL/9@8S],*,CO+2P#>(2KM,)XQ$LO*W$?'W<.J(;7W=.F[,G>-W=)FFW2+!O
M@;I]"\0^0<0Z7JN]W1UUW:X\)[G[*+E'7J?3VC=BOT"9P:-4_TWG?#/T_A.X
MZQ<1"\U#,J!X %=)DV($ \]7N(_Q==JVME>[??PBMM=F$F"#-E6[YD"[UQSH
MV#OMN/9ANV83.-!PH/&,H-%L><V3ID.-M83V-MO;?')/,367YG+^M\-BA\5+
ML;CM-4]7Z,3O#A8[B' 0X2 "(>+$.V[O_HD%FQD+W.!=-4]@*6Q#PP9:186]
MIF*WP6BWX^9;'1!YVHDOJ[6PUB[I+W+TTV;0W<FUD^NE<@UF47.%9M&6R;4+
M53VA%IO.C)>QKR)QOP/B7368<UB=PWK?'9_>:<.=5^)"6@XA'$(L7K2V=[S*
MRK7=00@7T7HD1_TJ4A;>:*[LHEC;#KIK/WYC)]'WH-GP6GN0='0GICO4<*BQ
M.M0X]$Z/=K]L; >"<MMGOIV/>#P43,8LBV'Z(8PU8$,N\T,TT+*#D6%#Q#&7
M(9T!,%"Z9CB>'2#\3-,IEL[XVR48=Q[W2M'[>/=+2%R>U(&' X]G (]V^]2!
MQVKM/A>V([MOYG0T%\!;F5BY$W1O7XGMQ^1FPSL\ZNS!";HNC.>PPV'':K&C
MX[6?KT1C1[##!?.>F(N='NKJL3XWTK==W&28I2)P=I[#:H?5]\#J1KWY;$F7
M'4%J9^4YY'#(L0@YCAQRN,#=<]AX?](:B:#&82I\**R=9YC*4I."F8<=0#(C
M DSI^BI*,NH)$CO+</_P?5VIF!V%]=,C[_ $_]\'_]UMLG!@X<#B"6!QZ+5:
MQUY[E1ME=PDL2OL/?L"JL@T!@1OOOO5U]YYT(,?EW$)Q70NDQI:\"GA;A5D4
M]P)IDI!/NOAM+^$!&G&5-+VT+\NM8_O!7YE)Y6!2O)=NK8DX ":YQ@G $[HE
MOUQO#,@^R_J^A06VO#0J78D$3&/K)=3X /"CR\,K/C$XR/SR=V_[*IC\](]W
M;T=I%/[TOU!+ 0(4 Q0    ( !*!J5C,;6?.[A0  -C8   1
M  "  0    !S<')Y+3(P,C0P-3 Y+FAT;5!+ 0(4 Q0    ( !*!J5@'@5BD
MPPD  %U]   1              "  1T5  !S<')Y+3(P,C0P-3 Y+GAS9%!+
M 0(4 Q0    ( !*!J5@+#(ZWP28  -AF @ /              "  0\?  !S
D<')Y+65X.3E?,2YH=&U02P4&      ,  P"[    _44

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>spry-20240509_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="spry-20240509.xsd" xlink:type="simple"/>
    <context id="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
        </entity>
        <period>
            <startDate>2024-05-09</startDate>
            <endDate>2024-05-09</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae"
      id="F_07235a38-c496-4174-8f10-a79c6a4a9416">0001671858</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae"
      id="F_d4c34378-3ae2-497a-a50c-680f964ce606">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae"
      id="F_a80573e7-3ca1-439e-b7c5-cbfd06498d33">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae"
      id="F_56ea463c-2535-4a40-8776-1034d798693a">2024-05-09</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae"
      id="F_5b2466a6-2d96-4f85-bf31-e0f15243a45e">ARS Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae"
      id="F_2afddfb2-683d-438a-a546-d2f8e4ec6e6d">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae"
      id="F_c5707acf-6e64-4914-bacf-54d9a8219b3b">001-39756</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae"
      id="F_3d5945bf-91e2-49ce-a398-e189743e1c3e">81-1489190</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae"
      id="F_32c39d13-333b-41d1-a705-d3d1bbe923c8">11682 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae"
      id="F_c239757e-3a88-41c7-9296-42da318037c2">Suite 120</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae"
      id="F_bb243c9a-5aba-4967-8f7b-1bb960e33cf1">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae"
      id="F_dbaff821-06fe-4321-9bd8-50a6efd3b933">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae"
      id="F_6ccd6ce5-255c-4c8d-8c08-c01c25da130b">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae"
      id="F_1ff39691-e150-4d79-bc62-00b7df29b113">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae"
      id="F_abb98eda-b482-4e68-ad61-18dc16f48f20">771-9307</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae"
      id="F_abbd9e97-f63a-4f93-bb1f-b6499b894385">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae"
      id="F_64587add-f5c0-4381-8429-6ee8bea9e963">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae"
      id="F_f646ce40-4c95-482e-983a-2cdd9c1065ff">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae"
      id="F_08ada183-175f-41a3-b6d2-f31c6ad86aed">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae"
      id="F_27555bba-b679-4ce4-adce-3596ee34e81c">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae"
      id="F_8bf93723-adc6-4d0b-9428-e84723956237">SPRY</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae"
      id="F_5870583b-7e8d-4069-b14b-005a6243df1c">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae"
      id="F_468e6093-94a7-41d7-9c59-41618c24e8f1">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_9397e41a-9e33-41a3-a2ab-4dca433c08ae"
      id="F_fdf79cbc-5594-4cb8-a0ec-db5b2d3fc3b6">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
